SOCS-3 antagonizes pro-apoptotic effects of TRAIL and resveratrol in prostate cancer cells

Prostate

Volumn 71, Issue 12, 2011, Pages 1357-1366

  Horndasch, Manuela ^a   Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

apoptosis; prostate cancer; resveratrol; suppressor of cytokine signaling 3; TRAIL

Indexed keywords

DEATH RECEPTOR 4; PROPIDIUM IODIDE; RESVERATROL; SMALL INTERFERING RNA; SUPPRESSOR OF CYTOKINE SIGNALING 3;

APOPTOSIS; ARTICLE; BIOASSAY; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN; CELL STRAIN DU145; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALE; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, SMALL INTERFERING; STILBENES; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 79957867725     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21353     Document Type: Article

References (24)

1. Nesterov A, Lu X, Johnson M, Miller GJ, Ivaschenko Y, Kraft AS,. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001; 276: 10767-10774. (Pubitemid 38089250)
2. Jang M, Lcai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM,. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 75: 218-220. (Pubitemid 127696281)
3. Gill C, Walsh SE, Morrissey C, Fitzpatrick JM, Watson RWG,. Resveratrol sensitizes androgen-independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate 2007; 67: 1641-1653. (Pubitemid 350036950)
4. Kubo M, Hanada T, Yoshimura A,. Suppressors of cytokine signaling and immunity. Nat Immunol 2003; 4: 1169-1176. (Pubitemid 37540685)
5. Alexander WS, Hilton DJ,. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004; 22: 503-529. (Pubitemid 38680432)
6. Larsen L, Ropke C,. Suppressors of cytokine signalling: SOCS. APMIS 2002; 110: 833-844. (Pubitemid 36177279)
7. Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA, Yoshimura A,. Cytokine-inducible SH2 proteine (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 1999; 4: 339-351. (Pubitemid 29359449)
8. Nicholson SE, De Souza D, Fabri LJ, Corbin J, Willson TA, Zhang JG, Silva A, Asimakis M, Farley A, Nash AD, Metcalf D, Hilton DJ, Nicola NA, Baca M,. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 2000; 97: 6493-6498. (Pubitemid 30412741)
9. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z,. Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol 2006; 169: 2199-2208. (Pubitemid 351181978)
10. Puhr M, Santer FR, Neuwirt H, Susani M, Nemeth JA, Hobisch A, Kenner L, Culig Z,. Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res 2009; 69: 7375-7384.
11. Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A, Culig Z,. Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. Endocr Relat Cancer 2007; 14: 1007-1019. (Pubitemid 351252432)
12. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z,. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 2001; 7: 2941-2948. (Pubitemid 32911405)
13. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH,. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
14. Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T,. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Prostate 2006; 66: 987-995. (Pubitemid 43849596)
15. Kamura T, Sato S, Haque D, Liu L, Kaelin WG Jr., Conaway RC, Conaway JW,. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 1998; 12: 3872-3881. (Pubitemid 29024849)
16. Zhang JG, Farley A, Nicholson SE, Willson TA, Zugaro LM, Simpson RJ, Moritz RL, Cary D, Richardson R, Hausmann G, Kile BJ, Kent SB, Alexander WS, Metcalf D, Hilton DJ, Nicola NA, Baca M,. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA 1999; 96: 2071-2076. (Pubitemid 29117869)
17. Fulda S, Debatin KM,. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004; 64: 337-346. (Pubitemid 38114116)
18. Fulda S, Debatin KM,. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2004; 23: 6702-6711. (Pubitemid 39280002)
19. Jazirehi AR, Bonavida B,. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2004; 3: 71-84. (Pubitemid 39193680)
20. Tsai SH, Lin-Shiau SY, Lin JK,. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br J Pharmacol 1999; 126: 673-680.
21. Holmes-McNary M, Baldwin AS Jr., Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 2000; 60: 3477-3483. (Pubitemid 30482167)
22. Stewart JR, O'Brian CA,. Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Invest New Drugs 2004; 22: 107-117. (Pubitemid 38270466)
23. Aziz MH, Nihal M, Fu VX, Jarrard DF, Ahmad N,. Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther 2006; 5: 1335-1341. (Pubitemid 43881327)
24. Altomare DA, Testa JR,. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24: 7455-7464. (Pubitemid 41637985)